{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:36:47Z","timestamp":1780497407685,"version":"3.54.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.coph.2018.03.011","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T17:54:28Z","timestamp":1522864468000},"page":"95-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy"],"prefix":"10.1016","volume":"40","author":[{"given":"Luigino","family":"Calzetta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriella","family":"Matera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2018.03.011_bib0245","series-title":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD\u20142018 Report","author":"GOLD","year":"2018"},{"key":"10.1016\/j.coph.2018.03.011_bib0250","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.pupt.2015.02.007","article-title":"Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD","volume":"31","author":"Cazzola","year":"2015","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.coph.2018.03.011_bib0255","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1164\/rccm.201209-1739PP","article-title":"beta2-agonist therapy in lung disease","volume":"187","author":"Cazzola","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coph.2018.03.011_bib0260","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1124\/pr.111.004580","article-title":"Pharmacology and therapeutics of bronchodilators","volume":"64","author":"Cazzola","year":"2012","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.coph.2018.03.011_bib0265","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.rmed.2017.06.020","article-title":"Impact of LABA\/LAMA combination on exercise endurance and lung hyperinflation in COPD: a pair-wise and network meta-analysis","volume":"129","author":"Calzetta","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.coph.2018.03.011_bib0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/16000617.0043-2016","article-title":"LABA\/LAMA combination in COPD: a meta-analysis on the duration of treatment","volume":"26","author":"Calzetta","year":"2017","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.coph.2018.03.011_sbref0275","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.chest.2016.02.646","article-title":"A systematic review with meta-analysis of dual bronchodilation with LAMA\/LABA for the treatment of stable COPD","volume":"149","author":"Calzetta","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.coph.2018.03.011_bib0280","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2147\/COPD.S125058","article-title":"Indacaterol\/glycopyrronium versus salmeterol\/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study","volume":"12","author":"Wedzicha","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.coph.2018.03.011_sbref0285","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.coph.2018.03.011_bib0290","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejphar.2015.05.020","article-title":"Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy","volume":"761","author":"Calzetta","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.coph.2018.03.011_bib0295","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.tiv.2007.03.003","article-title":"A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model","volume":"21","author":"Goldoni","year":"2007","journal-title":"Toxicol In Vitro"},{"key":"10.1016\/j.coph.2018.03.011_bib0300","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1177\/1087057114521867","article-title":"A new bliss independence model to analyze drug combination data","volume":"19","author":"Zhao","year":"2014","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.coph.2018.03.011_bib0305","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.pupt.2010.03.003","article-title":"The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD","volume":"23","author":"Cazzola","year":"2010","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.coph.2018.03.011_sbref0310","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12931-016-0386-8","article-title":"Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells","volume":"17","author":"Cazzola","year":"2016","journal-title":"Respir Res"},{"key":"10.1016\/j.coph.2018.03.011_sbref0315","first-page":"OA4407","article-title":"Protein tyrosin kinase and KCa++ channel: two faces of the same coin in LABA\/LAMA synergy","volume":"50","author":"Calzetta","year":"2017","journal-title":"Eur Resp J"},{"key":"10.1016\/j.coph.2018.03.011_bib0320","doi-asserted-by":"crossref","first-page":"11051","DOI":"10.1073\/pnas.89.22.11051","article-title":"Stimulatory and inhibitory regulation of calcium-activated potassium channels by guanine nucleotide-binding proteins","volume":"89","author":"Kume","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2018.03.011_bib0325","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1476-5381.1993.tb12851.x","article-title":"Evaluation of the relaxant effects of SCA40, a novel charybdotoxin-sensitive potassium channel opener, in guinea-pig isolated trachealis","volume":"108","author":"Laurent","year":"1993","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.coph.2018.03.011_bib0330","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1085\/jgp.113.1.45","article-title":"Noncatalytic inhibition of cyclic nucleotide-gated channels by tyrosine kinase induced by genistein","volume":"113","author":"Molokanova","year":"1999","journal-title":"J Gen Physiol"},{"key":"10.1016\/j.coph.2018.03.011_bib0335","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1152\/jappl.1988.65.6.2720","article-title":"Effects of atropine in ponies with recurrent airway obstruction","volume":"65","author":"Broadstone","year":"1988","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.coph.2018.03.011_bib0340","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.pupt.2008.02.003","article-title":"Effects of neuraminidase on equine isolated bronchi","volume":"21","author":"Matera","year":"2008","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.coph.2018.03.011_bib0345","first-page":"PA1810","article-title":"Interaction between tiotropium bromide and olodaterol in human bronchial smooth muscle","volume":"50","author":"Cazzola","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coph.2018.03.011_bib0350","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/17476348.2018.1442216","article-title":"Dual LABA\/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when and how","volume":"12","author":"Calzetta","year":"2018","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.coph.2018.03.011_sbref0355","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejphar.2014.10.025","article-title":"Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi","volume":"745","author":"Cazzola","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.coph.2018.03.011_bib0360","first-page":"A6275","article-title":"Interaction between tiotropium bromide and olodaterol in small human airways","volume":"195","author":"Rogliani","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coph.2018.03.011_sbref0365","first-page":"A6274","article-title":"Interaction between tiotropium bromide and olodaterol in human bronchial smooth muscle","volume":"195","author":"Calzetta","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coph.2018.03.011_sbref0370","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejphar.2017.07.026","article-title":"Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi","volume":"812","author":"Calzetta","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.coph.2018.03.011_sbref0375","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1080\/15412555.2017.1344627","article-title":"Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi","volume":"14","author":"Calzetta","year":"2017","journal-title":"COPD"},{"key":"10.1016\/j.coph.2018.03.011_sbref0380","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.rmed.2015.08.005","article-title":"Searching for the synergistic effect between aclidinium and formoterol: from bench to bedside","volume":"109","author":"Cazzola","year":"2015","journal-title":"Respir Med"},{"key":"10.1016\/j.coph.2018.03.011_sbref0385","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/15412555.2014.922172","article-title":"Translational study searching for synergy between glycopyrronium and indacaterol","volume":"12","author":"Cazzola","year":"2015","journal-title":"COPD"},{"key":"10.1016\/j.coph.2018.03.011_sbref0390","first-page":"PA1814","article-title":"Clinical synergism of LABA\/LAMA combinations in COPD patients","volume":"50","author":"Rogliani","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coph.2018.03.011_bib0395","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.rmed.2016.01.001","article-title":"Magnitude of umeclidinium\/vilanterol lung function effect depends on monotherapy responses: results from two randomised controlled trials","volume":"112","author":"Donohue","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.coph.2018.03.011_bib0400","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.2147\/COPD.S146338","article-title":"The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis","volume":"12","author":"Rogliani","year":"2017","journal-title":"Int J COPD"},{"key":"10.1016\/j.coph.2018.03.011_bib0405","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40264-016-0402-4","article-title":"Safety considerations with dual bronchodilator therapy in COPD: an update","volume":"39","author":"Matera","year":"2016","journal-title":"Drug Saf"},{"key":"10.1016\/j.coph.2018.03.011_bib0410","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1517\/14740338.2015.1093621","article-title":"The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease","volume":"14","author":"Tashkin","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.coph.2018.03.011_sbref0415","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2017.7720","article-title":"Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case\u2013control study","author":"Wang","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.coph.2018.03.011_bib0420","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1124\/jpet.112.198481","article-title":"In vitro pharmacological characterization of vilanterol, a novel long-acting beta2-adrenoceptor agonist with 24-hour duration of action","volume":"344","author":"Slack","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.coph.2018.03.011_bib0425","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1124\/jpet.105.098251","article-title":"In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-o ne (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action","volume":"317","author":"Battram","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.coph.2018.03.011_bib0430","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1124\/jpet.112.193284","article-title":"Pharmacological characterization of abediterol, a novel inhaled beta(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models","volume":"342","author":"Aparici","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.coph.2018.03.011_bib0435","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1124\/jpet.110.167007","article-title":"Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models","volume":"334","author":"Bouyssou","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.coph.2018.03.011_bib0440","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1183\/09031936.00032806","article-title":"Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi","volume":"29","author":"Naline","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coph.2018.03.011_bib0445","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1124\/jpet.109.152470","article-title":"Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs","volume":"330","author":"Casarosa","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.coph.2018.03.011_bib0450","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ejphar.2015.04.042","article-title":"Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi","volume":"761","author":"Rogliani","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.coph.2018.03.011_bib0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2018.01.003","article-title":"Comparison of the in vitro pharmacological profiles of long-acting muscarinic antagonists in human bronchus","author":"Naline","year":"2018","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.coph.2018.03.011_bib0460","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pupt.2014.05.005","article-title":"The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide","volume":"28","author":"Gavalda","year":"2014","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.coph.2018.03.011_bib0465","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1124\/jpet.110.170035","article-title":"Bronchodilator activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino] carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a potent, long-acting, and selective muscarinic M3 receptor antagonist","volume":"335","author":"Villetti","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.coph.2018.03.011_bib0470","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1124\/jpet.112.202051","article-title":"Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases","volume":"345","author":"Salmon","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.coph.2018.03.011_bib0475","first-page":"PA1055","article-title":"Interaction between tiotropium bromide and olodaterol in small human airways","volume":"50","author":"Calzetta","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coph.2018.03.011_bib0480","doi-asserted-by":"crossref","DOI":"10.1111\/jvp.12504","article-title":"Combining long-acting bronchodilators with different mechanisms of action: a pharmacological approach to optimize bronchodilation of equine airways","author":"Calzetta","year":"2018","journal-title":"J Vet Pharmacol Ther"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218300109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218300109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T22:30:22Z","timestamp":1530311422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489218300109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":48,"alternative-id":["S1471489218300109"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2018.03.011","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2018.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}